Edoxaban Affects TRAP-dependent Platelet Aggregation

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2020 Mar 30

PMID 32221807

Citations 4

Authors

Frantisek Nehaj

Juraj Sokol

Jela Ivankova

Michal Mokan

Marian Mokan

Jan Stasko

Affiliations

Soon will be listed here.

Abstract

Edoxaban is an oral anticoagulant drug and a direct factor Xa inhibitor. However, it is still not fully understood if and how edoxaban impacts platelet function. This prospective study aimed to assess in vitro platelet function in patients with atrial fibrillation (AF) receiving edoxaban. It was a single centre study quantifying platelet aggregation in 20 patients treated with edoxaban by light transmission aggregometry. The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly lower 2 h after taking edoxaban compared to baseline value (44.7 ± 32.03% vs. 73.3 ± 25.55%; p < 0.0001). In addition, we did not find any significant difference in results between the patient groups.The TRAP-induced platelet aggregation is reduced in non-valvular AF patients receiving edoxaban.

Citing Articles

Direct Oral Anticoagulant Treatment for Atherosclerosis-Induced Aortic Mural Thrombus in an Elderly Male With Aspirin Resistance.

Sugihara R, Kioka H, Sakata Y Cureus. 2024; 16(6):e62691.

PMID: 39036112 PMC: 11259519. DOI: 10.7759/cureus.62691.

Platelets and Their Role in Hemostasis and Thrombosis-From Physiology to Pathophysiology and Therapeutic Implications.

Scridon A Int J Mol Sci. 2022; 23(21).

PMID: 36361561 PMC: 9653660. DOI: 10.3390/ijms232112772.

The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.

Siriez R, Yildiz H, Bouvy C, Haguet H, Maloteau V, Hardy M Res Pract Thromb Haemost. 2022; 6(3):e12680.

PMID: 35434470 PMC: 9001858. DOI: 10.1002/rth2.12680.

Treatment with Edoxaban Attenuates Acute Stroke Severity in Mice by Reducing Blood-Brain Barrier Damage and Inflammation.

Bieber M, Foerster K, Haefeli W, Pham M, Schuhmann M, Kraft P Int J Mol Sci. 2021; 22(18).

PMID: 34576055 PMC: 8464921. DOI: 10.3390/ijms22189893.

References

Mann K, Brummel K, Butenas S . What is all that thrombin for?. J Thromb Haemost. 2003; 1(7):1504-14. DOI: 10.1046/j.1538-7836.2003.00298.x. View

Santos-Gallego C, Bayon J, Badimon J . Thrombi of different pathologies: implications for diagnosis and treatment. Curr Treat Options Cardiovasc Med. 2010; 12(3):274-91. DOI: 10.1007/s11936-010-0075-8. View

Streiff M, Agnelli G, Connors J, Crowther M, Eichinger S, Lopes R . Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016; 41(1):32-67. PMC: 4715858. DOI: 10.1007/s11239-015-1317-0. View

Rahman S, Eichinger C, Hlady V . Effects of upstream shear forces on priming of platelets for downstream adhesion and activation. Acta Biomater. 2018; 73:228-235. PMC: 5985216. DOI: 10.1016/j.actbio.2018.04.002. View

Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M . Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol. 2011; 155(1):30-44. DOI: 10.1111/j.1365-2141.2011.08793.x. View

Plitt A, Giugliano R . Edoxaban: Review of pharmacology and key phase I to III clinical trials. J Cardiovasc Pharmacol Ther. 2014; 19(5):409-16. DOI: 10.1177/1074248414523675. View

Burnett A, Mahan C, Vazquez S, Oertel L, Garcia D, Ansell J . Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016; 41(1):206-32. PMC: 4715848. DOI: 10.1007/s11239-015-1310-7. View

Cuker A, Husseinzadeh H . Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis. 2015; 39(3):288-94. PMC: 4608015. DOI: 10.1007/s11239-015-1185-7. View

Eikelboom J, Connolly S, Bosch J, Dagenais G, Hart R, Shestakovska O . Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14):1319-1330. DOI: 10.1056/NEJMoa1709118. View

10.

Oung A . Edoxaban (Savaysa) for the Prevention of Thromboembolic Events. Am Fam Physician. 2018; 97(8):529-530. View

11.

Davey M, LUSCHER E . Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature. 1967; 216(5118):857-8. DOI: 10.1038/216857a0. View

12.

Nehaj F, Sokol J, Ivankova J, Mokan M, Kovar F, Stasko J . First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans. Clin Appl Thromb Hemost. 2017; 24(6):914-919. PMC: 6714725. DOI: 10.1177/1076029617734310. View

13.

Nehaj F, Sokol J, Mokan M, Ivankova J, Mokan M . Thrombin Receptor Agonist Peptide-Induced Platelet Aggregation Is Reduced in Patients Receiving Dabigatran. Clin Appl Thromb Hemost. 2017; 24(2):268-272. PMC: 6714672. DOI: 10.1177/1076029617713871. View

14.

Ivanciu L, Stalker T . Spatiotemporal regulation of coagulation and platelet activation during the hemostatic response in vivo. J Thromb Haemost. 2015; 13(11):1949-59. PMC: 5847271. DOI: 10.1111/jth.13145. View

15.

Garcia-Ropero A, Santos-Gallego C, Zafar M, Badimon J . Dual versus triple antithrombotic therapy: is there a role for direct oral anticoagulants in arterial thrombosis?. Drugs Today (Barc). 2019; 55(3):197-214. DOI: 10.1358/dot.2019.55.3.2903216. View

16.

Michelson A, Ellis P, Barnard M, Matic G, Viles A, Kestin A . Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. Blood. 1991; 77(4):770-9. View

17.

Coughlin S . Thrombin signalling and protease-activated receptors. Nature. 2000; 407(6801):258-64. DOI: 10.1038/35025229. View

18.

Ivanciu L, Krishnaswamy S, Camire R . New insights into the spatiotemporal localization of prothrombinase in vivo. Blood. 2014; 124(11):1705-14. PMC: 4162104. DOI: 10.1182/blood-2014-03-565010. View